Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HAE 
Haemonetics Corporation (HAE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: HAE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $78.64
1 Year Target Price $78.64
| 3 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.79% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.65B USD | Price to earnings Ratio 16.62 | 1Y Target Price 78.64 |
Price to earnings Ratio 16.62 | 1Y Target Price 78.64 | ||
Volume (30-day avg) 10 | Beta 0.4 | 52 Weeks Range 50.68 - 94.98 | Updated Date 08/28/2025 |
52 Weeks Range 50.68 - 94.98 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When Before Market | Estimate 1.02 | Actual 1.1 |
Profitability
Profit Margin 12.14% | Operating Margin (TTM) 20.21% |
Management Effectiveness
Return on Assets (TTM) 6.52% | Return on Equity (TTM) 18.27% |
Valuation
Trailing PE 16.62 | Forward PE 11.16 | Enterprise Value 3549836091 | Price to Sales(TTM) 1.97 |
Enterprise Value 3549836091 | Price to Sales(TTM) 1.97 | ||
Enterprise Value to Revenue 2.64 | Enterprise Value to EBITDA 10.11 | Shares Outstanding 48177300 | Shares Floating 47598165 |
Shares Outstanding 48177300 | Shares Floating 47598165 | ||
Percent Insiders 1.15 | Percent Institutions 115.77 |
Upturn AI SWOT
Haemonetics Corporation
Company Overview
History and Background
Haemonetics was founded in 1971. It has grown from a company focused on blood processing technology to a global healthcare firm providing a range of products and services for blood management and hospital solutions.
Core Business Areas
- Hospital: Encompasses solutions for cell salvage, transfusion management, and patient blood management. Key products include disposables for cell salvage and transfusion software.
- Plasma: Focuses on products and services for plasma collection, including automated plasma collection devices and disposables.
- Blood Center: Offers solutions for blood donation, processing, and storage, including automated blood collection systems and blood bank software.
Leadership and Structure
Haemonetics is led by a CEO and executive management team. The organizational structure includes various departments such as R&D, operations, sales, and marketing. The Board of Directors provides oversight and governance.
Top Products and Market Share
Key Offerings
- Cell Saver Elite+ Autotransfusion System: A cell salvage system used in surgical procedures to recover and re-infuse a patient's own blood. Competitors include LivaNova, Medtronic, and Fresenius. Market share data is proprietary but Haemonetics is a major player.
- NexSys PCS System: Automated plasma collection system. Competitors include Terumo BCT and Grifols. Estimated 40% market share in automated plasma collection disposables (source: analyst reports).
- SafeTrace Tx: Transfusion management software. Competitors include MAK Systems and Mediware. Market share data varies by region.
Market Dynamics
Industry Overview
The blood management and hospital solutions industry is driven by factors such as aging populations, increasing surgical procedures, and the need for blood conservation. Growth is fueled by technological advancements and the rising demand for plasma-derived therapies.
Positioning
Haemonetics is a leader in blood management solutions with a strong position in plasma collection and hospital blood management. Competitive advantages include its established customer base, technological innovation, and global reach.
Total Addressable Market (TAM)
The global blood management market is expected to reach approximately $15 billion by 2028. Haemonetics is positioned to capture a significant share of this TAM through its various business segments.
Upturn SWOT Analysis
Strengths
- Strong market position in plasma collection
- Established customer base
- Technological innovation
- Global distribution network
- Diversified product portfolio
Weaknesses
- Dependence on hospital capital spending
- Exposure to regulatory changes
- Competition from larger medical device companies
- Fluctuations in plasma supply and demand
Opportunities
- Expansion into emerging markets
- Development of new blood management technologies
- Strategic acquisitions
- Increasing adoption of patient blood management programs
- Growth in plasma-derived therapies
Threats
- Intense competition
- Pricing pressures
- Product recalls
- Economic downturns
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- TER
- GRFS
- LIVN
- MTD
Competitive Landscape
Haemonetics faces competition from larger medical device companies with broader product portfolios. Its strengths include its focus on blood management and its established customer relationships.
Major Acquisitions
Cardiva Medical
- Year: 2021
- Acquisition Price (USD millions): 475
- Strategic Rationale: Expanded Haemonetics' portfolio of hospital products and technologies, adding vascular closure systems used in interventional cardiology and radiology procedures.
Growth Trajectory and Initiatives
Historical Growth: Haemonetics has experienced moderate growth in recent years, driven by its plasma and hospital businesses. Expansion into new markets and product innovation have contributed to growth.
Future Projections: Analyst estimates project continued growth for Haemonetics, driven by increasing demand for plasma-derived therapies and the adoption of patient blood management programs. Revenue growth is expected to be in the mid-single digits.
Recent Initiatives: Recent initiatives include the launch of new plasma collection technologies, expansion of its transfusion management software platform, and strategic acquisitions.
Summary
Haemonetics has a strong market presence in plasma collection and hospital blood management. Key strengths include technological innovation and a global distribution network. However, it faces competition and is exposed to regulatory changes. Future growth depends on expansion into new markets and product development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haemonetics Corporation
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 1991-05-09 | CEO, President & Director Mr. Christopher A. Simon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3023 | Website https://www.haemonetics.com |
Full time employees 3023 | Website https://www.haemonetics.com | ||
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.